共 50 条
- [1] Week 144 Results of a Phase II, Randomized, Multicenter Trial Assessing the Safety and Efficacy of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)[J]. NEUROLOGY, 2013, 80Hauser, StephenLi, DavidCalabresi, PeterO'Connor, PaulBar-Or, AmitBarkhof, FrederikSauter, AnnetteLeppert, DavidMasterman, DonnaTinbergen, JeroenKappos, Ludwig
- [2] Ocrelizumab in relapsing-remitting multiple sclerosis: 72-week efficacy and safety results of a phase II, randomised, placebo-controlled, multi-centre trial[J]. JOURNAL OF NEUROLOGY, 2011, 258 : 14 - 14Kappos, L.Li, D.Calabresi, P.O'Connor, P.Bar-Or, A.Barkhof, F.Yin, M.Leppert, D.Glanzman, R.Tinbergen, J.Hauser, S.
- [3] Long-Term Efficacy and Safety of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Week 96 Results of a Phase II, Randomized, Multicenter Trial[J]. NEUROLOGY, 2012, 78Hauser, StephenKappos, LudwigLi, DavidCalabresi, PeterO'Connor, PaulBar-Or, AmitBarkhof, FrederikWells, ChrisLeppert, DavidGlanzman, RobertTinbergen, Jeroen
- [4] Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial[J]. MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 446 - 447Zhao, Y.Li, D. K. B.Riddehough, A.Traboulsee, A.Masterman, D.Gilberg, F.Kappos, L.Leppert, D.
- [5] Safety and efficacy of rituximab in adults with relapsing-remitting multiple sclerosis: results of a phase II placebo-controlled, multicentre trial through 48 weeks[J]. MULTIPLE SCLEROSIS, 2007, 13 : S165 - S165Waubant, E.Hauser, S.Amold, D. L.Vollmer, T.Antel, J. P.Fox, R.Bar-Or, A.Panzara, M.Sarkar, N.Agarwal, S.Langer-Gould, A.Smith, C.
- [6] Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial[J]. MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S194 - S195Kappos, L.Li, D.Calabresi, P.O'Connor, P.Bar-Or, A.Barkhof, F.Yin, M.Leppert, D.Glanzmann, R.Tinbergen, J.Hauser, S. L.
- [7] Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial[J]. LANCET, 2011, 378 (9805): : 1779 - 1787Kappos, LudwigLi, DavidCalabresi, Peter A.O'Connor, PaulBar-Or, AmitBarkhof, FrederikYin, MingLeppert, DavidGlanzman, RobertTinbergen, JeroenHauser, Stephen L.
- [8] Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis A Randomized, Placebo-Controlled Trial[J]. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2021, 8 (03):Bellmann-Strobl, JudithPaul, FriedemannWuerfel, JensDoerr, JanInfante-Duarte, CarmenHeidrich, ElmiraKoertgen, BenedictBrandt, AlexanderPfuller, CasparRadbruch, HelenaRust, RebekkaSiffrin, VolkerAktas, OrhanHeesen, ChristophFaiss, JuergenHoffmann, FrankLorenz, MarioZimmermann, BennoGroppa, SergiuWernecke, Klaus-DieterZipp, Frauke
- [9] A phase II randomized, placebo-controlled, multicenter trial of rituximab in adults with relapsing remitting multiple sclerosis (RRMS)[J]. NEUROLOGY, 2007, 68 (12) : A99 - A100Hauser, StephenWaubant, EmmanuelleArnold, DouglasVollmer, TimothyAntel, JackFox, RobertBar-Or, AmitSarkar, NeenaLanger-Gould, AnnettePanzara, MichaelSmith, Craig
- [10] Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial[J]. MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 140 - 141Kappos, L.Li, D.Calabresi, P.O'Connor, P.Bar-Or, A.Barkhof, F.Wells, C.Leppert, D.Masterman, D.Tinbergen, J.Hauser, S. L.